Data Sheet (Cat.No.T67930)

TargetMol

CWI1-2

Chemical Properties



CAS No. : 2408590-36-1

Formula: C22H17Cl3N6O3

Molecular Weight: 519.77

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	CWI1-2 is a potent IGF2BP2 inhibitor that inhibits its interaction with M6A-modified target transcripts by binding IGF2BP2. CWI1-2 has anti-leukemic activity and can induce apoptosis and differentiation.
Targets(IC50)	Apoptosis
In vitro	CWI1-2 demonstrates excellent anti-leukemia efficacy in a concentration range of 0-1 μM for 24 hours[1].
In vivo	Administered intravenously at 5 mg/kg once daily for 7-10 days, CWI1-2 significantly delays the onset of leukemia and extends the survival time in BMT (bone marrow transplantation) recipient B6.SJL (CD45.1) mice, with no apparent impact on body weight [1].

Solubility Information

Solubility	DMSO: 245 mg/mL (471.36 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.85 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9239 mL	9.6196 mL	19.2393 mL
5 mM	0.3848 mL	1.9239 mL	3.8479 mL
10 mM	0.1924 mL	0.962 mL	1.9239 mL
50 mM	0.0385 mL	0.1924 mL	0.3848 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10.